FDA approves venglustat, the first treatment for neurological symptoms of type 3 Gaucher disease
- On 18 November 2026 the FDA approved Sanofi's Infilbray (venglustat).
- It treats the neurological symptoms of type 3 Gaucher disease, a rare inherited disorder.
- Venglustat is an oral drug that crosses the blood-brain barrier.
- Approval is based on the Phase III LEAP2MONO trial.
The FDA approved Sanofi's Infilbray (venglustat) on 18 November 2026 to treat the neurological symptoms of type 3 Gaucher disease, which previously had no targeted therapy in the US.
What is type 3 Gaucher disease?
It is a rare inherited disorder in which fatty substances called glycosphingolipids build up in the spleen, liver, bone marrow, lungs and nervous system. Build-up in the brain causes neuroinflammation, cognitive problems and poor balance.
How it works
Venglustat is an oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier, so it reaches the brain, unlike enzyme replacement therapy, which controls only the body-wide symptoms.
The trial
The application relied on the Phase III LEAP2MONO study in adults and children aged 12 and over with neurological symptoms whose systemic disease was stable on enzyme replacement therapy. Venglustat met both primary endpoints, and the application received priority review.
Sources: FDA — Novel Drug Approvals 2026, Pharmaceutical Technology
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is venglustat (Infilbray)?
Venglustat is an oral Sanofi drug approved by the FDA on 18 November 2026 for the neurological symptoms of type 3 Gaucher disease.
What is type 3 Gaucher disease?
Type 3 Gaucher disease is a rare inherited disorder in which glycosphingolipids build up in organs and the nervous system, causing body-wide and neurological symptoms.
How does venglustat differ from enzyme replacement therapy?
Venglustat crosses the blood-brain barrier and reaches the brain, while enzyme replacement therapy controls only the body-wide symptoms of Gaucher disease.
Which trial supported venglustat's approval?
Venglustat's approval was supported by the Phase III LEAP2MONO trial in adults and children aged 12 and over, where it met both primary endpoints.
Is venglustat the first treatment for neurological Gaucher symptoms?
Yes. Venglustat is the first US-approved therapy targeting the neurological symptoms of type 3 Gaucher disease.



